Literature DB >> 7532625

Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly cross-reactive C. trachomatis-neutralizing antibodies.

A D Murdin1, H Su, M H Klein, H D Caldwell.   

Abstract

Trachoma and sexually transmitted diseases caused by Chlamydia trachomatis are major health problems worldwide. Epitopes from the variable domains of the major outer membrane protein are candidates for vaccine development. We have constructed hybrid polioviruses expressing sequences from major outer membrane protein variable domains I and IV. Antisera to the hybrids could, in combination, strongly neutralize 8 of the 12 C. trachomatis serovars most commonly associated with oculogenital infections and weakly neutralize the others.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532625      PMCID: PMC173119          DOI: 10.1128/iai.63.3.1116-1121.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.

Authors:  S van der Werf; J Bradley; E Wimmer; F W Studier; J J Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

Review 2.  Chlamydial infections (third of three parts).

Authors:  J Schachter
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

3.  Local antibody response to poliovaccine in the human female genital tract.

Authors:  P L Ogra; S S Ogra
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

4.  Engineering poliovirus as a vaccine vector for the expression of diverse antigens.

Authors:  R Andino; D Silvera; S D Suggett; P L Achacoso; C J Miller; D Baltimore; M B Feinberg
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

5.  Neutralization of Chlamydia trachomatis cell culture infection by serovar-specific monoclonal antibodies.

Authors:  M E Lucero; C C Kuo
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

6.  Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease.

Authors:  S M Golding; R S Hedger; P Talbot
Journal:  Res Vet Sci       Date:  1976-03       Impact factor: 2.534

7.  An animal model of trachoma II. The importance of repeated reinfection.

Authors:  H R Taylor; S L Johnson; R A Prendergast; J Schachter; C R Dawson; A M Silverstein
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-10       Impact factor: 4.799

8.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

9.  In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein.

Authors:  R Peeling; I W Maclean; R C Brunham
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Importance of reinfection in the pathogenesis of trachoma.

Authors:  J T Grayston; S P Wang; L J Yeh; C C Kuo
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec
View more
  10 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

3.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection.

Authors:  Sandra G Morrison; Richard P Morrison
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection.

Authors:  K H Ramsey; T W Cotter; R D Salyer; G S Miranpuri; M A Yanez; C E Poulsen; J L DeWolfe; G I Byrne
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain.

Authors:  D J Zhang; X Yang; C Shen; R C Brunham
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

8.  B-cell-deficient mice develop complete immune protection against genital tract infection with Chlamydia trachomatis.

Authors:  M Johansson; M Ward; N Lycke
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

9.  Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells.

Authors:  S G Morrison; H Su; H D Caldwell; R P Morrison
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

10.  Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars.

Authors:  M N Starnbach; M J Bevan; M F Lampe
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.